AlgoTx announces results of its phase 2 'ACT' trial of ATX01 in chemotherapy-induced peripheral neuropathy
- AlgoTx completed a 276-patient Phase 2 trial, 'ACT', for ATX01 targeting chemotherapy-induced peripheral neuropathy (CIPN).
- The trial was double-blind and placebo-controlled, testing two concentrations of ATX01, with a focus on the 15% concentration.
- ATX01 showed promising efficacy, particularly at 15%, but a high placebo effect in some sites affected overall results.
- Future studies will explore strategies to mitigate placebo effects and further evaluate ATX01's efficacy.
Read more
Solid Biosciences reports positive initial clinical data from next-generation Duchenne gene therapy candidate SGT-003
- Phase 1/2 INSPIRE DUCHENNE trial shows 110% average microdystrophin expression in first 3 participants.
- SGT-003 well-tolerated in 6 participants with no serious adverse events; enrollment continues.
- Potential cardiac benefits observed; company plans FDA meeting for accelerated approval in mid-2025.
- Trial aims to dose 20 participants by Q4 2025, with additional trial sites expected by end of 2025.
Read more
